AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$ORKA

Quinlan Paul T sold $936K of ORKA

Quinlan Paul T (General Counsel) sold 10,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $93.64 ($92.37–$95.31, $0.94M total) across 4 trades on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Quinlan Paul T
Published Sep 21, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Bearish
medium confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKABearishLow
01

Why it matters

The disclosed sale is modest and likely already priced in, offering limited trading edge.

02

Market read

Provides a fresh insider‑sale data point for ORKA; minimal broader market relevance.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset the negative signal.

Relevance 4/10Novelty 4/10Timing: filing date today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$ORKABearishMedium confidence
Context

General Counsel Quinlan Paul T sold 10,000 ORKA shares for $936,417 via a 10b5‑1 plan on 2026‑09‑21.

Expected impact

Potential short‑term dip of 1‑2% as market digests the sale.

Evidence & confidence

A 10b5‑1 sale by a senior officer indicates a willingness to liquidate, but the amount ($936k) is small for a mid‑cap biotech, limiting price impact.

Market effects

Sector

Minor signal for biotech sector; no broader impact.

Regional

U.S. market only; negligible regional effect.

Global

Limited to investors tracking ORKA.

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged plan and not indicative of future weakness.

Key entities

  • company
    Oruka Therapeutics, Inc.

    Biotech firm developing therapies; ticker ORKA.

  • person
    Quinlan Paul T

    General Counsel and officer of Oruka Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 27
$ORKAHighAI 8/10

H.C. Wainwright reiterates Oruka Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $120 price target for Oruka Therapeutics (ORKA) after positive Phase 2b trial results for ORKA-001 in psoriasis. The stock rose 14% last week to $90.33, up 226% over a year. Analysts' price targets range from $117 to $200. The trial showed 61% of high-dose patients achieved PASI 100 at Week 16. Phase 3 trials are planned for 2027.

investing.com2 min
OCT 27
$ORKAMedAI 8/10

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Oruka Therapeutics reported that its drug ORKA-001 achieved 61% complete skin clearance in a Phase IIb psoriasis study. The company plans to advance the 600-milligram dose into Phase III in early 2027, pending regulatory discussions. Oruka also expects to report week 52 data from the EVERLAST-A study in December, which will test the drug's potential for annual maintenance dosing. The company has over $1 billion in cash, providing runway through a potential biologics license application filing.

finance.yahoo.com2 min